Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 45 | 2024 | 1648 | 5.760 |
Why?
|
Stomach Neoplasms | 33 | 2024 | 1422 | 3.760 |
Why?
|
Esophagogastric Junction | 20 | 2024 | 341 | 3.170 |
Why?
|
Adenocarcinoma | 43 | 2024 | 6313 | 2.540 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 56 | 2024 | 11709 | 2.080 |
Why?
|
Cisplatin | 16 | 2022 | 1645 | 1.030 |
Why?
|
Camptothecin | 17 | 2017 | 588 | 1.010 |
Why?
|
Fluorouracil | 23 | 2024 | 1631 | 0.990 |
Why?
|
Platinum | 1 | 2022 | 218 | 0.750 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2553 | 0.670 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2023 | 4023 | 0.620 |
Why?
|
Neoadjuvant Therapy | 10 | 2024 | 2821 | 0.590 |
Why?
|
Gastrointestinal Neoplasms | 7 | 2023 | 951 | 0.570 |
Why?
|
Leucovorin | 13 | 2022 | 641 | 0.530 |
Why?
|
Clinical Protocols | 1 | 2021 | 1436 | 0.490 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 320 | 0.460 |
Why?
|
Esophagectomy | 5 | 2021 | 466 | 0.440 |
Why?
|
Gastrectomy | 3 | 2021 | 670 | 0.410 |
Why?
|
Pancreatic Neoplasms | 12 | 2024 | 5349 | 0.410 |
Why?
|
Colonic Neoplasms | 8 | 2017 | 2523 | 0.390 |
Why?
|
Antineoplastic Agents | 14 | 2020 | 13591 | 0.380 |
Why?
|
Neuroendocrine Tumors | 7 | 2022 | 650 | 0.370 |
Why?
|
Organoplatinum Compounds | 8 | 2019 | 405 | 0.370 |
Why?
|
Paclitaxel | 8 | 2024 | 1728 | 0.320 |
Why?
|
Aged | 69 | 2024 | 168217 | 0.300 |
Why?
|
Research Design | 2 | 2021 | 6154 | 0.300 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2024 | 211 | 0.290 |
Why?
|
Colorectal Neoplasms | 14 | 2023 | 6852 | 0.280 |
Why?
|
Middle Aged | 68 | 2024 | 219560 | 0.260 |
Why?
|
Surgery Department, Hospital | 1 | 2007 | 177 | 0.250 |
Why?
|
Aged, 80 and over | 40 | 2024 | 58681 | 0.250 |
Why?
|
Deoxycytidine | 11 | 2024 | 870 | 0.250 |
Why?
|
Disease-Free Survival | 12 | 2017 | 6821 | 0.240 |
Why?
|
Carboplatin | 3 | 2022 | 788 | 0.230 |
Why?
|
Male | 76 | 2024 | 358742 | 0.230 |
Why?
|
Neoplasm Staging | 16 | 2021 | 11152 | 0.230 |
Why?
|
Humans | 109 | 2024 | 758381 | 0.230 |
Why?
|
Epirubicin | 3 | 2021 | 83 | 0.220 |
Why?
|
Combined Modality Therapy | 10 | 2021 | 8530 | 0.220 |
Why?
|
Survival Rate | 13 | 2021 | 12721 | 0.220 |
Why?
|
Adult | 59 | 2024 | 219916 | 0.220 |
Why?
|
Female | 76 | 2024 | 390316 | 0.220 |
Why?
|
Taxoids | 3 | 2020 | 668 | 0.220 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2006 | 623 | 0.220 |
Why?
|
Neoplasm Metastasis | 15 | 2024 | 4901 | 0.220 |
Why?
|
Antibodies, Monoclonal | 11 | 2024 | 9160 | 0.210 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 87 | 0.200 |
Why?
|
Drug Administration Schedule | 11 | 2016 | 4839 | 0.200 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.190 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.190 |
Why?
|
Anus Neoplasms | 3 | 2012 | 329 | 0.190 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2000 | 70 | 0.180 |
Why?
|
Treatment Outcome | 32 | 2024 | 64379 | 0.180 |
Why?
|
Keratins | 1 | 2021 | 497 | 0.180 |
Why?
|
Barrett Esophagus | 1 | 2004 | 490 | 0.170 |
Why?
|
Rectal Neoplasms | 3 | 2015 | 1152 | 0.170 |
Why?
|
Quinazolines | 9 | 2012 | 1360 | 0.170 |
Why?
|
Colectomy | 1 | 2004 | 692 | 0.160 |
Why?
|
Dacarbazine | 3 | 2012 | 559 | 0.160 |
Why?
|
Claudins | 3 | 2024 | 115 | 0.160 |
Why?
|
Lymph Node Excision | 2 | 2020 | 1303 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2024 | 996 | 0.160 |
Why?
|
Nausea | 2 | 2024 | 677 | 0.160 |
Why?
|
Liver Neoplasms | 6 | 2014 | 4313 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 884 | 0.150 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2020 | 423 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 707 | 0.140 |
Why?
|
Maximum Tolerated Dose | 6 | 2012 | 876 | 0.140 |
Why?
|
Deglutition Disorders | 3 | 2016 | 625 | 0.130 |
Why?
|
Double-Blind Method | 5 | 2023 | 12262 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 544 | 0.130 |
Why?
|
Administration, Oral | 6 | 2016 | 3993 | 0.130 |
Why?
|
Quality-Adjusted Life Years | 1 | 2022 | 1722 | 0.130 |
Why?
|
Anorexia | 1 | 2016 | 154 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2018 | 2004 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 1056 | 0.120 |
Why?
|
Carcinoma | 2 | 2020 | 2330 | 0.120 |
Why?
|
Survival Analysis | 13 | 2021 | 10112 | 0.120 |
Why?
|
Microsatellite Instability | 3 | 2022 | 715 | 0.120 |
Why?
|
Guidelines as Topic | 2 | 2019 | 1386 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2021 | 2943 | 0.120 |
Why?
|
Medical Oncology | 5 | 2023 | 2312 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2912 | 0.120 |
Why?
|
Radiopharmaceuticals | 2 | 2018 | 2634 | 0.120 |
Why?
|
Alcohol Drinking | 2 | 2004 | 4020 | 0.120 |
Why?
|
Triazoles | 1 | 2020 | 902 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 9273 | 0.110 |
Why?
|
Sirolimus | 2 | 2013 | 1533 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2006 | 638 | 0.110 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1612 | 0.100 |
Why?
|
Laparoscopy | 1 | 2004 | 2147 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1828 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 4 | 2014 | 2047 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.100 |
Why?
|
Palliative Care | 4 | 2017 | 3570 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3527 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2009 | 2292 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 747 | 0.090 |
Why?
|
Informed Consent | 1 | 2017 | 1003 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 851 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2640 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 426 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2000 | 3709 | 0.090 |
Why?
|
Preoperative Care | 2 | 2013 | 2249 | 0.090 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 529 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2022 | 5484 | 0.080 |
Why?
|
Immunoconjugates | 1 | 2017 | 949 | 0.080 |
Why?
|
Disease Progression | 7 | 2017 | 13468 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6493 | 0.080 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 83 | 0.080 |
Why?
|
Quality of Life | 4 | 2024 | 13286 | 0.080 |
Why?
|
Genomic Instability | 1 | 2012 | 704 | 0.080 |
Why?
|
Carcinoid Tumor | 2 | 2009 | 228 | 0.080 |
Why?
|
Time Factors | 7 | 2021 | 39873 | 0.070 |
Why?
|
Patient Participation | 1 | 2017 | 1436 | 0.070 |
Why?
|
Biliary Tract Neoplasms | 1 | 2009 | 184 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 759 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39060 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2307 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 31 | 0.070 |
Why?
|
Tegafur | 1 | 2006 | 39 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1322 | 0.070 |
Why?
|
Endostatins | 1 | 2006 | 168 | 0.070 |
Why?
|
Digestive System Neoplasms | 1 | 2006 | 81 | 0.070 |
Why?
|
Prognosis | 5 | 2019 | 29558 | 0.060 |
Why?
|
Young Adult | 8 | 2024 | 58808 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1404 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2057 | 0.060 |
Why?
|
Vinblastine | 1 | 2006 | 487 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5331 | 0.060 |
Why?
|
Video-Assisted Surgery | 1 | 2004 | 51 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5691 | 0.060 |
Why?
|
Recombinant Proteins | 3 | 2023 | 6520 | 0.060 |
Why?
|
Pheochromocytoma | 1 | 2006 | 328 | 0.060 |
Why?
|
Esophageal Fistula | 1 | 2003 | 60 | 0.060 |
Why?
|
Terminally Ill | 1 | 2005 | 240 | 0.060 |
Why?
|
Data Collection | 1 | 2013 | 3322 | 0.050 |
Why?
|
Retrospective Studies | 9 | 2023 | 80170 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1130 | 0.050 |
Why?
|
Boronic Acids | 1 | 2006 | 914 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2825 | 0.050 |
Why?
|
Radiotherapy Dosage | 2 | 2021 | 2896 | 0.050 |
Why?
|
Gallbladder Neoplasms | 1 | 2004 | 190 | 0.050 |
Why?
|
CpG Islands | 1 | 2007 | 1221 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8503 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2024 | 266 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2006 | 346 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2022 | 3480 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2053 | 0.050 |
Why?
|
Quality Improvement | 1 | 2017 | 3806 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1610 | 0.050 |
Why?
|
Survival | 1 | 2021 | 160 | 0.050 |
Why?
|
Vomiting | 1 | 2024 | 651 | 0.050 |
Why?
|
Practice Guidelines as Topic | 3 | 2015 | 7377 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2007 | 1268 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3840 | 0.050 |
Why?
|
Pyrazines | 1 | 2006 | 1198 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10146 | 0.040 |
Why?
|
North America | 1 | 2024 | 1276 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 629 | 0.040 |
Why?
|
Albumins | 1 | 2023 | 575 | 0.040 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2006 | 733 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 383 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2009 | 10747 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 640 | 0.040 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 191 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1705 | 0.040 |
Why?
|
Edema | 1 | 2023 | 768 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2005 | 1718 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2000 | 627 | 0.040 |
Why?
|
Prospective Studies | 3 | 2018 | 54136 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 611 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1745 | 0.040 |
Why?
|
Isotretinoin | 1 | 1999 | 132 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 785 | 0.040 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 2210 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2194 | 0.040 |
Why?
|
Pamphlets | 1 | 2017 | 71 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2012 | 6457 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2416 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2004 | 7985 | 0.030 |
Why?
|
Gastroesophageal Reflux | 1 | 2003 | 816 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1826 | 0.030 |
Why?
|
Risk Assessment | 5 | 2021 | 23883 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2022 | 2504 | 0.030 |
Why?
|
Gene Amplification | 1 | 2020 | 1085 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 596 | 0.030 |
Why?
|
ras Proteins | 2 | 2014 | 1049 | 0.030 |
Why?
|
Oxaloacetates | 1 | 2014 | 5 | 0.030 |
Why?
|
Interferon-alpha | 1 | 1999 | 918 | 0.030 |
Why?
|
Risk Factors | 5 | 2021 | 73806 | 0.030 |
Why?
|
China | 1 | 2020 | 2337 | 0.030 |
Why?
|
Neoplasms | 2 | 2017 | 22030 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 5248 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2009 | 617 | 0.030 |
Why?
|
Feeding Behavior | 1 | 2005 | 3183 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1724 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 165 | 0.030 |
Why?
|
DNA Methylation | 1 | 2007 | 4373 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5789 | 0.030 |
Why?
|
Video Recording | 1 | 2017 | 954 | 0.020 |
Why?
|
United States | 4 | 2020 | 72140 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3615 | 0.020 |
Why?
|
Clinical Competence | 1 | 2007 | 4775 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 653 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 517 | 0.020 |
Why?
|
Mutation | 3 | 2024 | 29915 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4549 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2685 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5629 | 0.020 |
Why?
|
Thalidomide | 2 | 2006 | 884 | 0.020 |
Why?
|
Perioperative Care | 1 | 2018 | 1028 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2024 | 7590 | 0.020 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 350 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1074 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
Medicare | 1 | 2007 | 6741 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 1998 | 6293 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4485 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6439 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 454 | 0.020 |
Why?
|
Smoking | 1 | 2003 | 9042 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2796 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1651 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1725 | 0.020 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.020 |
Why?
|
Digestive System Surgical Procedures | 1 | 2011 | 575 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 45 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2610 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2500 | 0.020 |
Why?
|
Tocopherols | 1 | 2005 | 44 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2012 | 1764 | 0.020 |
Why?
|
Incidence | 1 | 2003 | 21273 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2697 | 0.020 |
Why?
|
Self Administration | 1 | 2006 | 390 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 677 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22006 | 0.020 |
Why?
|
Radiotherapy | 1 | 2011 | 1504 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 319 | 0.010 |
Why?
|
Gene Deletion | 1 | 2012 | 2666 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2010 | 1630 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 358 | 0.010 |
Why?
|
Pilot Projects | 1 | 2018 | 8554 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5199 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1067 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18357 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8506 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2925 | 0.010 |
Why?
|
Piperidines | 1 | 2012 | 1639 | 0.010 |
Why?
|
Massachusetts | 2 | 2007 | 8823 | 0.010 |
Why?
|
DNA Copy Number Variations | 1 | 2012 | 2012 | 0.010 |
Why?
|
Patient Selection | 1 | 2015 | 4244 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3261 | 0.010 |
Why?
|
Animals | 3 | 2023 | 167777 | 0.010 |
Why?
|
Carotenoids | 1 | 2005 | 620 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2005 | 726 | 0.010 |
Why?
|
Mice | 2 | 2023 | 81107 | 0.010 |
Why?
|
Radiography | 1 | 2012 | 6955 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1378 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 2020 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2006 | 1314 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7980 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2215 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2209 | 0.010 |
Why?
|
Recurrence | 1 | 2011 | 8426 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2858 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2009 | 3208 | 0.010 |
Why?
|
Vitamin D | 1 | 2012 | 3283 | 0.010 |
Why?
|
Decision Making | 1 | 2013 | 3915 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2012 | 20500 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2021 | 15638 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3211 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2005 | 21017 | 0.010 |
Why?
|
Fatty Acids | 1 | 2005 | 1803 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2014 | 7843 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 4106 | 0.010 |
Why?
|
Signal Transduction | 2 | 2011 | 23341 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2005 | 2443 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2014 | 4761 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3521 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 16886 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2800 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12440 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12436 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3443 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10653 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12096 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2005 | 11070 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 13959 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 17768 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 87888 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2005 | 20052 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 36285 | 0.000 |
Why?
|